XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Kurt A Jenkins; Miso Park; Magali Pederzoli-Ribeil; Ugur Eskiocak; Parker Johnson; Wilson Guzman; Megan McLaughlin; Deborah Moore-Lai; Caitlin O’Toole; Zhen Liu; Benjamin Nicholson; Veronica Flesch; Huawei Qiu; Tim Clackson; Ronan C O’Hagan; Ulrich Rodeck; Margaret Karow; Jennifer O’Neil; John C Williams

doi:10.1136/jitc-2023-007785

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF

PDF +
Supplementary
Material

Oncolytic and local immunotherapy

Original research

XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Main menu

Online download statistics by month:

Online download statistics by month:

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month:

Read the full text or download the PDF:

Log in using your username and password